Charles River Laboratories | CRL - Bruttoergebnis Vom Umsatz

Aktienkurs
165.46
Täglich Wechseln
1.62 0.99%
Monatlich
-4.08%
Jährlich
41.55%
Q2 Prognose
166.17




Bruttoergebnis Vom Umsatz Veränderung Datum
Agilent USD 946M 44M 2025-12
Align Technology USD 736.59M 53M 2026-03
Bio-Rad Laboratories USD 345.2M 1.8M 2025-12
Bruker USD 449.2M 69.8M 2025-12
Cardinal Health USD 2.5B 101M 2026-03
Charles River Laboratories USD 271.96M 39.43M 2025-12
Cigna USD 56.45B 50.29B 2025-09
Concord Medical Services Hldg CNY -37.42M 26.25M 2023-06
CVS Health USD 13.57B 239M 2025-12
Danaher USD 3.59B 375M 2026-03
Dentsply International USD 443M 2M 2025-12
Elevance Health USD 11.68B 889M 2025-12
Galapagos EUR -13.57M 74.82M 2025-09
Humana USD 4.82B 754M 2025-06
Illumina USD 759M 26M 2025-12
Incyte USD 1.17B 217.51M 2026-03
Intrexon USD -297K 167K 2024-06
IQVIA Holdings USD 1.12B 32M 2025-12
Laboratory Of America USD 993.2M 31.9M 2025-12
Lonza CHF 1.29B 248M 2025-06
McKesson USD 3.68B 143M 2025-12
Merck EUR 2.96B 252M 2025-12
Mettler Toledo International USD 675.44M 65.98M 2025-12
Novartis USD 10.25B 570M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Quest Diagnostics USD 906M 33M 2026-03
Revvity USD 421.66M 47.06M 2025-12
Thermo Fisher Scientific USD 4.49B 146M 2026-03
United Therapeutics USD 315.5M 286.6M 2025-12
UnitedHealth USD 18.49B 2.14B 2025-12
Veradigm USD 83.44M 3.95M 2022-09
Waters USD 557.42M 97.44M 2025-12
West Pharmaceutical Services USD 296.4M 7.5M 2026-03